|
1.
|
|
10 p, 859.5 KB |
Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks
/
Zhang, Y. (University of Oxford) ;
Ghose, U. (University of Oxford) ;
Buckley, N.J. (University of Oxford) ;
Engelborghs, S. (Vrije Universiteit Brussel) ;
Sleegers, K. (University of Antwerp) ;
Frisoni, G.B. (Department of Psychiatry. University of Geneva) ;
Wallin, A. (University of Gothenburg) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, J. (University of Zürich) ;
Martinez-Lage, P. (CITA-Alzheimer Foundation) ;
Legido-Quigley, C. (Steno Diabetes Center) ;
Barkhof, F. (University College London) ;
Zetterberg, H. (Kong Kong Center for Neurodegenerative Diseases) ;
Visser, P.J. (VU University Medical Center) ;
Bertram, L. (University of Oslo) ;
Lovestone, S. (Janssen RD) ;
Nevado-Holgado, Alejo (University of Oxford) ;
Shi, L. (University of Oxford) ;
Universitat Autònoma de Barcelona
Background and objective: Blood-based biomarkers represent a promising approach to help identify early Alzheimer's disease (AD). Previous research has applied traditional machine learning (ML) to analyze plasma omics data and search for potential biomarkers, but the most modern ML methods based on deep learning has however been scarcely explored. [...]
2022 -  10.3389/fnagi.2022.1040001
Frontiers in aging neuroscience, Vol. 14 (29 2022) , p. 1040001
|
|
|
2.
|
|
52 p, 705.6 KB |
Role of Amyloid-β and Tau Proteins in Alzheimer's Disease : Confuting the Amyloid Cascade
/
Gulisano, W. (Department of Biomedical and Biotechnological Sciences. Section of Physiology. University of Catania) ;
Maugeri, Daniele (Department of Biomedical and Biotechnological Sciences. Section of Physiology. University of Catania) ;
Baltrons Soler, Ma. Antonia (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Fà, Mauro (Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Department of Medicine. Columbia University) ;
Amato, Arianna (Department of Anaesthesiology. Università Cattolica Del Sacro Cuore) ;
Palmeri, Agostino (Department of Biomedical and Biotechnological Sciences. Section of Physiology. University of Catania) ;
D'Adamio, Luciano (Department of Pharmacology. Physiology and Neuroscience. Rutgers University) ;
Grassi, Claudio (Institute of Human Physiology. Università Cattolica Del Sacro Cuore) ;
Devanand, D.P. (Department of Psychiatry. Columbia University. College of Phys. and Surg.) ;
Honig, Lawrence S. (Department of Neurology. Columbia University. College of Phys. and Surg.) ;
Puzzo, Daniela (Department of Biomedical and Biotechnological Sciences. Section of Physiology. University of Catania) ;
Arancio, Ottavio (Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Department of Medicine. Columbia University)
The "Amyloid Cascade Hypothesis" has dominated the Alzheimer's disease (AD) field in the last 25 years. It posits that the increase of amyloid-β (Aβ) is the key event in AD that triggers tau pathology followed by neuronal death and eventually, the disease. [...]
2018 - 10.3233/JAD-179935
Journal of Alzheimer's disease, Vol. 64 Núm. s1 (2018) , p. S611-S631
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
18 p, 1.0 MB |
Polyoxometalate-Decorated Gold Nanoparticles Inhibit β-Amyloid Aggregation and Cross the Blood-Brain Barrier in a µphysiological Model
/
Perxés Perich, Marta (Institut Català de Nanociència i Nanotecnologia) ;
Palma-Florez, Sujey (Institut de Ciència i Tecnologia de Barcelona) ;
Solé, Clara (Institut de Ciència i Tecnologia de Barcelona) ;
Goberna-Ferrón, Sara (Institut Català de Nanociència i Nanotecnologia) ;
Samitier, Josep (Institut de Ciència i Tecnologia de Barcelona) ;
Gómez-Romero, Pedro 1959- (Institut Català de Nanociència i Nanotecnologia) ;
Mir, Mònica (Institut de Ciència i Tecnologia de Barcelona) ;
Lagunas, Anna (Institut de Ciència i Tecnologia de Barcelona)
Alzheimer's disease is characterized by a combination of several neuropathological hallmarks, such as extracellular aggregates of beta amyloid (Aβ). Numerous alternatives have been studied for inhibiting Aβ aggregation but, at this time, there are no effective treatments available. [...]
2023 - 10.3390/nano13192697
Nanomaterials, Vol. 13, Issue 19 (October 2023) , art. 2697
|
|
|
6.
|
|
11 p, 814.5 KB |
Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals : Examining the Necessity to Adjust for Biomarker Status in Normative Data
/
Bos, Isabelle (Maastricht University) ;
Vos, Stephanie J.B. (Maastricht University) ;
Jansen, Willemijn J. (Maastricht University) ;
Vandenberghe, Rik (KU Leuven) ;
Gabel, Silvy (KU Leuven) ;
Estanga, Ainara (CITA-Alzheimer Foundation) ;
Ecay-Torres, Mirian (CITA-Alzheimer Foundation) ;
Tomassen, Jori (Vrije Universiteit Amsterdam) ;
den Braber, Anouk (Vrije Universiteit Amsterdam) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Sala, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Wallin, Anders (University of Gothenburg Sahlgrenska Academy) ;
Kettunen, Petronella (University of Oxford) ;
Molinuevo, José Luis (Universitat Pompeu Fabra) ;
Rami, Lorena (Hopsital Clínic Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS)) ;
Chetelat, Gaël (Université de Caen-Normandie GIP Cyceron) ;
de la Sayette, Vincent (CHU de Caen) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Freund-Levi, Yvonne (Norrtälje Hospital Tiohundra) ;
Johannsen, Peter (University of Copenhagen) ;
Novak, Gerald P. (Janssen Pharmaceutical Research and Development) ;
Ramakers, Inez (Maastricht University) ;
Verhey, Frans R. (Maastricht University) ;
Visser, Pieter J. (Vrije Universiteit Amsterdam) ;
Universitat Autònoma de Barcelona
We investigated whether amyloid-β (Aβ) and tau affected cognition in cognitively normal (CN) individuals, and whether norms for neuropsychological tests based on biomarker-negative individuals would improve early detection of dementia. [...]
2018 - 10.3389/fnagi.2018.00193
Frontiers in aging neuroscience, Vol. 10 (25 2018) , p. 193
|
|
|
7.
|
|
12 p, 1.2 MB |
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease
/
Startin, Carla M. (LonDownS Consortium (London Down Syndrome Consortium)) ;
Ashton, Nicholas J. (University of Gothenburg) ;
Hamburg, Sarah (LonDownS Consortium (London Down Syndrome Consortium)) ;
Hithersay, Rosalyn (LonDownS Consortium (London Down Syndrome Consortium)) ;
Wiseman, Frances K. (University College London) ;
Mok, Kin Y. (Hong Kong University of Science and Technology) ;
Hardy, John (University College London) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Lovestone, Simon (University of Oxford) ;
Parnetti, Lucilla (University of Perugia) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ;
Hye, Abdul (Maudsley NHS Foundation) ;
Fisher, Elisabeth ;
Nizetic, Dean ;
Tybulewicz, Victor ;
Karmiloff-Smith, Anette ;
Al-Janabi, Tamara ;
Zhang, David ;
Strydom, André (LonDownS Consortium (London Down Syndrome Consortium)) ;
Universitat Autònoma de Barcelona
Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and controls will aid in understanding AD development in DS. [...]
2019 - 10.1186/s13195-019-0477-0
Alzheimer's research & therapy, Vol. 11 Núm. 1 (21 2019) , p. 26
|
|
|
8.
|
|
11 p, 783.1 KB |
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
/
Shi, Liu (University of Oxford) ;
Westwood, Sarah (University of Oxford) ;
Baird, Alison L. (University of Oxford) ;
Winchester, Laura (University of Oxford) ;
Dobricic, Valerija (University of Lübeck) ;
Kilpert, Fabian (University of Lübeck) ;
Hong, Shengjun (University of Lübeck) ;
Franke, Andre (Christian-Albrechts-University of Kiel) ;
Hye, Abdul (King's College London) ;
Ashton, Nicholas J. (South London and Maudsley NHS Foundation) ;
Morgan, Angharad R. (Cardiff University) ;
Bos, Isabelle (Maastricht University) ;
Vos, Stephanie J.B. (Amsterdam UMC. University Medical Center) ;
Buckley, Noel J (University of Oxford) ;
Kate, Mara ten (Amsterdam UMC. University Medical Center) ;
Scheltens, Philip (Amsterdam UMC. University Medical Center) ;
Vandenberghe, Rik (University Hospitals Leuven (Bèlgica)) ;
Gabel, Silvy (Laboratory for Cognitive Neurology) ;
Meersmans, Karen (Laboratory for Cognitive Neurology) ;
Engelborghs, Sebastiaan (VUB University Hospital Brussels (UZ Brussel)) ;
De Roeck, Ellen E. (Institute Born-Bunge. University of Antwerp) ;
Sleegers, Kristel (Center for Molecular Neurology. VIB) ;
Frisoni, Giovanni B. (IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli) ;
Blin, Olivier (Aix-Marseille Université) ;
Richardson, Jill C. (GlaxoSmithKline R&D) ;
Bordet, Régis (University of Lille) ;
Molinuevo, José Luis (Hospital Clínic i Provincial de Barcelona) ;
Rami, Lorena (Universitat Pompeu Fabra) ;
Wallin, Anders (Sahlgrenska Academy at University of Gothenburg) ;
Kettunen, Petronella (University of Oxford) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans (Maastricht University) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, Julius (Geneva University Hospitals) ;
Peyratout, Gwendoline (Lausanne University Hospital) ;
Martinez-Lage, Pablo (Fundación CITA-Alzhéimer Fundazioa) ;
Tainta, Mikel (CITA-Alzheimer Foundation) ;
Johannsen, Peter Copenhagen University Hospital ;
Teunissen, Charlotte E. (Vrije Universiteit Amsterdam) ;
Freund-Levi, Yvonne (King's College London) ;
Frölich, Lutz (University of Heidelberg) ;
Legido-Quigley, Cristina (Steno Diabetes Center) ;
Barkhof, Frederik (UCL Institutes of Neurology and Healthcare Engineering) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ;
Baker, Susan (Janssen R&D) ;
Morgan, B.Paul (Cardiff University) ;
Streffer, Johannes (Janssen R&D. LLC) ;
Visser, Pieter Jelle (Karolinska Institutet (Estocolm, Suècia)) ;
Bertram, Lars (University of Oslo) ;
Lovestone, Simon (University of Oxford) ;
Nevado-Holgado, Alejo (University of Oxford) ;
Universitat Autònoma de Barcelona
Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. [...]
2019 - 10.1016/j.jalz.2019.06.4951
Alzheimer's & Dementia, Vol. 15 Núm. 11 (november 2019) , p. 1478-1488
|
|
|
9.
|
|
9 p, 1012.4 KB |
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity : A cross-sectional analysis from the AB255 Study
/
Pérez-Grijalba, Virginia (Araclon Biotech S.L.) ;
Arbizu, Javier (Clínica Universidad de Navarra) ;
Romero, Judith (Araclon Biotech S.L.) ;
Prieto, Elena (Clínica Universidad de Navarra) ;
Pesini, Pedro (Araclon Biotech S.L.) ;
Sarasa, Leticia (Araclon Biotech S.L.) ;
Guillen, Fernando (Clínica Universidad de Navarra) ;
Monleón, Inmaculada (Araclon Biotech S.L.) ;
San-José, Itziar (Araclon Biotech S.L.) ;
Martínez-Lage, Pablo (Fundación CITA-Alzheimer) ;
Munuera, Josep (Institut de Recerca Sant Joan de Déu) ;
Hernández, Isabel (Instituto de Salud Carlos III) ;
Buendía, Mar (Universitat Internacional de Catalunya) ;
Sotolongo-Grau, Oscar (Universitat Internacional de Catalunya) ;
Alegret, Montserrat (Instituto de Salud Carlos III) ;
Ruiz, Agustín (Instituto de Salud Carlos III) ;
Tárraga, Lluís (Instituto de Salud Carlos III) ;
Boada, Mercè (Instituto de Salud Carlos III) ;
Sarasa, Manuel (Araclon Biotech S.L.) ;
Goñi Imízcoz, Miguel (Hospital Divino Vallés (Burgos)) ;
Pujadas, Francesc ;
Villarejo, Alberto ;
Frank, Ana ;
Peña-Casanova, Jordi ;
Fernández, Manuel ;
Piñol, Gerard ;
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ;
Gil, Pedro ;
Pascual, Luis F. ;
Aguilar Barberà, Miquel ;
Frisoni, Giovanni B. ;
Matias-Guiu, Jorge ;
Andreasen, Niels ;
Antúnez, Carmen ;
Universitat Autònoma de Barcelona
To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer's disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by amyloid-PET. [...]
2019 - 10.1186/s13195-019-0549-1
Alzheimer's research & therapy, Vol. 11 Núm. 1 (january 2019) , p. 96
|
|
|
10.
|
|
22 p, 986.7 KB |
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
/
Kim, Min (Steno Diabetes Center Copenhagen) ;
Snowden, Stuart (University of Cambridge) ;
Suvitaival, Tommi (Steno Diabetes Center Copenhagen) ;
Ali, Ashfaq (Steno Diabetes Center Copenhagen) ;
Merkler, David J. (University of South Florida) ;
Ahmad, Tahmina (King's College London) ;
Westwood, Sarah (University of Oxford) ;
Baird, Alison (University of Oxford) ;
Proitsi, Petroula (King's College London) ;
Nevado-Holgado, Alejo (University of Oxford) ;
Hye, Abdul (Steno Diabetes Center Copenhagen) ;
Bos, Isabelle (Maastricht University) ;
Vos, Stephanie (Maastricht University) ;
Vandenberghe, Rik (University Hospitals Leuven (Bèlgica)) ;
Teunissen, Charlotte (Amsterdam Neuroscience) ;
ten Kate, Mara (Amsterdam Neuroscience) ;
Scheltens, Philip (Amsterdam UMC. University Medical Center) ;
Gabel, Silvy (KU Leuven) ;
Meersmans, Karen (KU Leuven) ;
Blin, Olivier ;
Richardson, Jill (GlaxoSmithKline R&D) ;
De Roeck, Ellen (University of Antwerp) ;
Sleegers, Kristel (VIB) ;
Bordet, Régis (University of Lille) ;
Rami Gonzalez, Lorena (Hospital Clínic i Provincial de Barcelona) ;
Kettunen, Petronella (John Radcliffe Hospital (Oxford, Regne Unit)) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans (Maastricht University) ;
Sala, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Peyratout, Gwendoline (Lausanne University Hospital) ;
Tainta, Mikel (CITA-Alzheimer Foundation) ;
Johannsen, Peter (Copenhagen University Hospital) ;
Freund-Levi, Yvonne (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Frölich, Lutz (University of Heidelberg) ;
Dobricic, Valerija (University of Lübeck) ;
Engelborghs, Sebastiaan (University Hospital Antwerp (Bèlgica)) ;
Frisoni, Giovanni B. (University of Geneva) ;
Molinuevo, José Luis (Hospital Clínic i Provincial de Barcelona) ;
Wallin, Anders (University of Gothenburg) ;
Popp, Julius (Geneva University Hospitals) ;
Martinez-Lage, Pablo (CITA-Alzheimer Foundation) ;
Bertram, Lars (University of Lübeck) ;
Barkhof, Frederik (Amsterdam Neuroscience) ;
Ashton, Nicholas J (University of Gothenburg) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Zetterberg, Henrik (UK Dementia Research Institute) ;
Streffer, Johannes (Janssen Pharmaceutical Companies) ;
Visser, Pieter J. (Amsterdam Neuroscience) ;
Lovestone, Simon (University of Oxford) ;
Legido-Quigley, Cristina (Steno Diabetes Center Copenhagen) ;
Universitat Autònoma de Barcelona
A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. [...]
2019 - 10.1016/j.jalz.2019.03.004
Alzheimer's & Dementia, Vol. 15 Núm. 6 (june 2019) , p. 817-827
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
